Literature DB >> 12918074

Hereditary ovarian cancer in Poland.

Janusz Menkiszak1, Jacek Gronwald, Bohdan Górski, Anna Jakubowska, Tomasz Huzarski, Tomasz Byrski, Małgorzata Foszczyńska-Kłoda, Olga Haus, Hanna Janiszewska, Magdalena Perkowska, Izabela Brozek, Ewa Grzybowska, Helena Zientek, Stanisław Góźdź, Beata Kozak-Klonowska, Krzysztof Urbański, Roman Miturski, Jerzy Kowalczyk, Anna Pluzańska, Stanisław Niepsuj, Jan Koc, Marek Szwiec, Kazimierz Drosik, Andrzej Mackiewicz, Katarzyna Lamperska, Elwira Strózyk, Dariusz Godlewski, Małgorzata Stawicka, Bernard Waśko, Marek Bebenek, Andrzej Rozmiarek, Izabella Rzepka-Górska, Steven A Narod, Jan Lubiński.   

Abstract

There is increasing evidence that hereditary factors play a greater role in ovarian cancer than in any of the other common cancers of adulthood. This is attributable, to a large extent, to a high frequency of mutations in the BRCA1 or BRCA2 genes. In Poland, 3 common founder mutations in BRCA1 account for the majority of families with identified BRCA mutations. Our study was conducted in order to estimate the prevalence of any of 3 founder BRCA1 mutations (5382insC, C61G and 4153delA) in 364 unselected women with ovarian cancer, and among 177 women with ovarian cancer and a family history of breast or ovarian cancer. A mutation was identified in 49 out of 364 unselected women with ovarian cancer (13.5%) and in 58 of 177 women with familial ovarian cancer (32.8%). The majority of women with ovarian cancer and a BRCA1 mutation have no family history of breast or ovarian cancer. The high frequency of BRCA1 mutations in Polish women with ovarian cancer supports the recommendation that all Polish women with ovarian cancer should be offered testing for genetic susceptibility, and that counseling services be made available to them and to their relatives. It is important that mutation surveys be conducted in other countries prior to the introduction of national genetic screening programs. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12918074     DOI: 10.1002/ijc.11338

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  33 in total

1.  On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations.

Authors:  Nancy Hamel; Bing-Jian Feng; Lenka Foretova; Dominique Stoppa-Lyonnet; Steven A Narod; Evgeny Imyanitov; Olga Sinilnikova; Laima Tihomirova; Jan Lubinski; Jacek Gronwald; Bohdan Gorski; Thomas v O Hansen; Finn C Nielsen; Mads Thomassen; Drakoulis Yannoukakos; Irene Konstantopoulou; Vladimir Zajac; Sona Ciernikova; Fergus J Couch; Celia M T Greenwood; David E Goldgar; William D Foulkes
Journal:  Eur J Hum Genet       Date:  2010-12-01       Impact factor: 4.246

Review 2.  Epidemiology of Patients with Ovarian Cancer with and Without a BRCA1/2 Mutation.

Authors:  Elisabete Weiderpass; Jerzy E Tyczynski
Journal:  Mol Diagn Ther       Date:  2015-12       Impact factor: 4.074

3.  High prevalence of two BRCA1 mutations, 4154delA and 5382insC, in Latvia.

Authors:  Laima Tikhomirova; Olga Sinicka; Dagnija Smite; Janis Eglitis; Shirley V Hodgson; Aivars Stengrevics
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

4.  Prevalence of two BRCA1 mutations, 5382insC and 300T > G, in ovarian cancer patients from Ukraine.

Authors:  I Gorodetska; S Serga; T Lahuta; L Ostapchenko; S Demydov; N Khranovska; O Skachkova; M Inomistova; O Kolesnik; V Svintsitsky; N Tsip; A Peresunko; N Kmit'; O Manzhura; Z Rossokha; O Popova; H Salomakhina; S Kyriachenko; I Kozeretska
Journal:  Fam Cancer       Date:  2017-10       Impact factor: 2.375

5.  BRCA1 4153delA founder mutation in Russian ovarian cancer patients.

Authors:  Nadezhda Yu Krylova; Oksana S Lobeiko; Anna P Sokolenko; Aglaya G Iyevleva; Maxim E Rozanov; Natalia V Mitiushkina; Madina M Gergova; Tatiana V Porhanova; Adel F Urmancheyeva; Sergey Ya Maximov; Alexandr V Togo; Evgeny N Imyanitov
Journal:  Hered Cancer Clin Pract       Date:  2006-09-15       Impact factor: 2.857

6.  BRCA1 and BRCA2 germline mutations in Korean ovarian cancer patients.

Authors:  Myong Cheol Lim; Sokbom Kang; Sang-Soo Seo; Sun-Young Kong; Bo-Yon Lee; Seon-Kyung Lee; Sang-Yoon Park
Journal:  J Cancer Res Clin Oncol       Date:  2009-06-05       Impact factor: 4.553

Review 7.  The contribution of BRCA1 and BRCA2 to ovarian cancer.

Authors:  Susan J Ramus; Simon A Gayther
Journal:  Mol Oncol       Date:  2009-02-10       Impact factor: 6.603

8.  Loss of heterozygosity at BRCA1/2 loci in hereditary and sporadic ovarian cancers.

Authors:  I Brozek; K Ochman; J Debniak; L Morzuch; M Ratajska; M Stepnowska; M Stukan; J Emerich; J Limon
Journal:  J Appl Genet       Date:  2009       Impact factor: 3.240

9.  Large family with both parents affected by distinct BRCA1 mutations: implications for genetic testing.

Authors:  Anna P Sokolenko; Dmitry A Voskresenskiy; Aglaya G Iyevleva; Elena M Bit-Sava; Nadezhda I Gutkina; Maxim S Anisimenko; Nathalia Yu Sherina; Nathalia V Mitiushkina; Yulia M Ulibina; Olga S Yatsuk; Olga A Zaitseva; Evgeny N Suspitsin; Alexandr V Togo; Valery A Pospelov; Sergey P Kovalenko; Vladimir F Semiglazov; Evgeny N Imyanitov
Journal:  Hered Cancer Clin Pract       Date:  2009-01-26       Impact factor: 2.857

10.  BRCA1 testing.

Authors:  Bohdan Górski; Jan Lubinski
Journal:  Hered Cancer Clin Pract       Date:  2008-06-15       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.